Latest Safety News

Polymetals Resources has reported a fatal underground incident at its Endeavor Mine in NSW, resulting in two deaths and a suspension of operations as investigations proceed.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

EQ Resources Limited reported a robust Q1 FY2026 with soaring tungsten prices, operational upgrades, and significant capital raises to fuel mine expansions.

Jupiter Mines reported a 5% increase in manganese production for Q1 FY2026, yet sales volumes and EBITDA declined, reflecting a complex market environment. Despite these shifts, the company maintains a strong cash position and steady manganese prices.

WA Kaolin Limited has reported a remarkable surge in sales volumes and revenue for the September 2025 quarter, driven by operational upgrades and expanding market reach. The company’s forward orders and product diversification signal robust growth ahead.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Robex Resources reports strong Q3 2025 progress with Kiniero Gold Project on track for Q4 first gold pour, raises C$148 million via accelerated warrant exercise, and announces merger plans with Predictive Discovery.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.

MC Mining reports strong safety performance and steady progress on its flagship Makhado coal project, while Uitkomst Colliery implements a turnaround plan amid production setbacks. Cash reserves have strengthened following significant share subscription payments.

Geopacific Resources advances its Woodlark Gold Project with promising drilling results at Kamwak and a crucial mining lease extension, while strengthening strategic partnerships and progressing its feasibility study.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

AJ Lucas Group Limited reported a robust start to FY26, driven by a significant UK dispute settlement and improved Australian operations. The company’s liquidity and operational upgrades position it well despite ongoing challenges.